Bicara Therapeutics Inc. ... (BCAX)
Bicara Therapeutics Common Stock Statistics
Share Statistics
Bicara Therapeutics Common Stock has 54.42M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 54.42M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 40.73K |
| FTD / Avg. Volume | 9.49% |
Short Selling Information
The latest short interest is 4.52M, so 8.31% of the outstanding shares have been sold short.
| Short Interest | 4.52M |
| Short % of Shares Out | 8.31% |
| Short % of Float | 13.89% |
| Short Ratio (days to cover) | 6.93 |
Valuation Ratios
The PE ratio is -23.31 and the forward PE ratio is -8.13. Bicara Therapeutics Common Stock's PEG ratio is -0.63.
| PE Ratio | -23.31 |
| Forward PE | -8.13 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -8.14 |
| P/FCF Ratio | -26.22 |
| PEG Ratio | -0.63 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Bicara Therapeutics Inc. Common Stock.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.32, with a Debt / Equity ratio of 0.
| Current Ratio | 15.32 |
| Quick Ratio | 15.32 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | -0.44 |
| Cash Flow / Debt | -69.45 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.35% and return on capital (ROIC) is 26.93%.
| Return on Equity (ROE) | 0.35% |
| Return on Assets (ROA) | -0.22% |
| Return on Capital (ROIC) | 26.93% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.62M |
| Employee Count | 32 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 5K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -0.46, so Bicara Therapeutics Common Stock's price volatility has been lower than the market average.
| Beta | -0.46 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 14.93 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 53.54 |
| Average Volume (20 Days) | 429.03K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -39.89M |
| Net Income | -51.98M |
| EBITDA | -51.96M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1 |
Balance Sheet
The company has 230.44M in cash and 657K in debt, giving a net cash position of 229.78M.
| Cash & Cash Equivalents | 230.44M |
| Total Debt | 657K |
| Net Cash | 229.78M |
| Retained Earnings | -153.02M |
| Total Assets | 524.17M |
| Working Capital | 507.03M |
Cash Flow
In the last 12 months, operating cash flow was -45.63M and capital expenditures -586K, giving a free cash flow of -46.21M.
| Operating Cash Flow | -45.63M |
| Capital Expenditures | -586K |
| Free Cash Flow | -46.21M |
| FCF Per Share | -0.89 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BCAX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.26% |
| FCF Yield | -6.16% |
Analyst Forecast
The average price target for BCAX is $40, which is 190.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $40 |
| Price Target Difference | 190.3% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 29.62 |
| Piotroski F-Score | 2 |